Last reviewed · How we verify
LTLD
LTLD is a Small molecule drug developed by UMC Utrecht. It is currently in Phase 1 development. Also known as: ThermoDox, Lyso-Thermosensitive Liposomal Doxorubicin.
LTLD (Thermally Sensitive Liposomal Doxorubicin) is being studied in clinical trials for various types of cancer, including breast cancer, pediatric cancer, solid tumors, rhabdomyosarcoma, and Ewing sarcoma. It is used in combination with radiation therapy and superficial hyperthermia in these trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LTLD |
|---|---|
| Also known as | ThermoDox, Lyso-Thermosensitive Liposomal Doxorubicin |
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors (PHASE2)
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (PHASE3)
- A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (PHASE1)
- Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients (PHASE2)
- Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (PHASE1)
- Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTLD CI brief — competitive landscape report
- LTLD updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about LTLD
What is LTLD?
Who makes LTLD?
Is LTLD also known as anything else?
What development phase is LTLD in?
Related
- Manufacturer: UMC Utrecht — full pipeline
- Also known as: ThermoDox, Lyso-Thermosensitive Liposomal Doxorubicin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing